Clinical Efficacy and Safety of Naftopidil Treatment for Patients with Benign Prostatic Hyperplasia and Hypertension: A Prospective, Open-Label Study
Yonsei Medical Journal
; : 800-806, 2017.
Article
in En
| WPRIM
| ID: wpr-81892
Responsible library:
WPRO
ABSTRACT
PURPOSE: To investigate the efficacy and safety of naftopidil for benign prostatic hyperplasia (BPH) patients, mainly focusing on changes in blood pressure (BP). MATERIALS AND METHODS: Of a total of 118 patients, 90 normotensive (NT) and 28 hypertensive (HT) patients were randomly assigned to be treated with naftopidil 50 mg or 75 mg for 12 weeks, once-daily. Safety and efficacy were assessed by analyzing changes from baseline in systolic/diastolic BP and total International Prostate Symptom Score (IPSS) at 4 and 12 weeks. Adverse events (AEs), obstructive/irritative subscores, quality of life (QoL) score, maximum urinary flow rate (Qmax), and benefit, satisfaction with treatment, and willingness to continue treatment (BSW) questionnaire were also analyzed. RESULTS: Naftopidil treatment decreased mean systolic BP by 18.7 mm Hg for the HT 50 mg group (p86% of all patients agreed to continue their current medications. CONCLUSION: Our results suggest that naftopidil treatment in BPH patients with hypertension allows for optimal management of BP within the normal range.
Key words
Full text:
1
Index:
WPRIM
Main subject:
Prostate
/
Prostatic Hyperplasia
/
Quality of Life
/
Reference Values
/
Blood Pressure
/
Prospective Studies
/
Treatment Outcome
/
Hypertension
Type of study:
Observational_studies
Limits:
Humans
Language:
En
Journal:
Yonsei Medical Journal
Year:
2017
Type:
Article